CytoSorb in Endocarditis Patients Undergoing Valve Surgery

Objectives: The Cytosorb Adsorber (Cytosorbents Corporation, USA) was designed to eliminate inflammatory mediators during cardiopulmonary bypass to decrease inflammatory response and improve outcome. Existing data describe Cytosorb therapy to be safe. The aim of this study was to evaluate outcome of endocarditis patients undergoing valve surgery with the Cytosorb Adsorber. This is, to our knowledge, the first retrospective propensity-weighted analysis, which evaluates the potential of Cytosorb in endocarditis patients.